MetaCap

Focus Universal (FCUV) vs Niki BioSolutions (NIKI)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Niki BioSolutions is the larger company by market cap ($4.9 million vs $3.9 million), about 1.3 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

FCUV-12.64%NIKI-66.24%
+63%-5%-74%
Oct 7, 20261 yearNov 20, 2026
FCUV-5.52%NIKI-60.75%
+76%+5%-67%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

FCUV versus NIKI key metrics
MetricFCUVNIKI
Share price$3.94$1.57
Market cap$3.87M$4.90M
1-day change-8.37%-6.55%
YTD return—-85.19%
1-year return—-87.92%
5-year return—-99.18%
EPS (TTM)$-14.92$-2.90
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$255.02K—
Revenue growth (YoY)-35.95%—
Net income (latest FY)$-4.79M$-1.36M
Gross margin-13.82%—
Operating margin-1918.75%—
Net margin-1877.39%—
52-week high$158.40$14.40
52-week low$1.79$1.42
Distance from 52-week high-97.51%-89.10%
Average volume2.04M97.67K
Shares outstanding982.01K2.94M
Employees371
SectorIndustrialsIndustrials
IndustryIndustrial Machinery/ComponentsIndustrial Machinery/Components

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Focus Universal

FCUV stock →

Focus Universal Inc. develops and commercializes universal smart technologies and instruments in the United States.

Industrials · Industrial Machinery/Components · 37 employees

About Niki BioSolutions

NIKI stock →

Niki BioSolutions, Inc., through its subsidiaries, operates as a clinical-stage biopharmaceutical company and engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in a Phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in a Phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa.

Industrials · Industrial Machinery/Components · 1 employees

FCUV vs NIKI FAQ

Which is bigger, Focus Universal or Niki BioSolutions?

Niki BioSolutions (NIKI) is larger, with a market capitalization of $4.90M compared with $3.87M for Focus Universal (FCUV).

Are Focus Universal and Niki BioSolutions in the same industry?

Yes. Both are classified in the Industrial Machinery/Components industry within the Industrials sector.

More comparisons